Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease

European Journal of Endocrinology

Volumn 162, Issue 4, 2010, Pages 677-684

  Höybye, Charlotte ^a   Ragnarsson, Oskar ^b   Jönsson, Peter J ^c   Koltowska Häggström, Maria ^c   Trainer, Peter ^d   Feldt Rasmussen, Ulla ^e   Biller, Beverly M K ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c PFIZER INC   (United States)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e Rigshospitalet   (Denmark)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CUSHING DISEASE; DIABETES MELLITUS; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RETROSPECTIVE STUDY;

ADENOMA; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 77950314879     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0836     Document Type: Article

References (29)

1. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM & Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 1526-1540.
2. de Boer H, Blok GJ & Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86.
3. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonennko P, Sönksen PH, Tanaka T & Thorner M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 83 382-395.
4. Verhelst J & Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002 62 239-412.
5. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, Endocrine Society's Clinical Guidelines Subcommittee & Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 1621-1634.
6. van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW & Romijn JA. Quality of life in patients after long-term biochemical cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2005 90 3279-3286.
7. Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Ståhl E, Monson JP, Westberg B, Wilton P, Wüster C & KIMS International Study Board of KIMS Study Group. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European Journal of Endocrinology 2002 146 67-74.
8. Johansson G, Sunnerhagen KS & Svensson J. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clinical Endocrinology 2004 60 550-559.
9. Colson A, Brooke AM, Walker D, Besser GM, Chew SL, Grossman AB, Jenkins PJ, Drake WM & Monson JP. Growth hormone deficiency and replacement in patients with treated Cushing's disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Hormone Research 2006 66 257-267.
10. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B & Luger A. Registries as a tool in evidence - based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiology and Drug Safety 2008 17 90-102.
11. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
12. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L & Wiren L. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383.
13. Filipsson H, Monson JP, Koltowska-Häggstrom M, Mattsson A & Johansson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3954-3961.
14. Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S & Thalassinos NC. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome. Clinical Endocrinology 2004 60 309-314.
15. Pecori GF, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sacco E, Scacchi M, Pontecorvi A & Cavagnini F. Significant GH, deficiency after long-term cure by surgery in adult patients with Cushing's disease. European Journal of Endocrinology 2007 156 233-239.
16. Hughes NR, Lisett CA & Shalet SM. Growth hormone status following treatment for Cushing's syndrome. Clinical Endocrinology 1999 51 61-66.
17. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K & Weeke J. Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism 2001 86 117-123.
18. Lindsay JR, Nansel T, Baid S, Gumowski J & Nieman LK. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. Journal of Clinical Endocrinology and Metabolism 2006 91 447-453.
19. Koltowska-Haggstrom M, Hennesy S, Mattsson AF, Monson JP & Kind P. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Hormone Research 2005 64 46-54.
20. Blevins LS, Sanai N, Kunwar S & Devin JK. An approach to the management of patients with residual Cushing's disease. Journal of Neuro-Oncology 2009 94 313-319.
21. Rosén T, Edén S, Larsson G, Wilhelmsen L & Bengtsson BÅ. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 195-200.
22. Bulow B, Hagmar L, Mikoczy Z, Nordström CH & Erfurth EM. Increased cardiovascular mortality in patients with hypopituitarism. Clinical Endocrinology 1997 46 75-81.
23. Svensson J, Bengtsson B-Å, Rosén T, Odén A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312.
24. Beshyah SA & Johnston D. Cardiovascular disease and risk factors in adults with hypopituitarism. Clinical Endocrinology 1999 50 1-15.
25. Abdu TA, Neary R, Elhadd TA, Akber M & Clayton RN. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clinical Endocrinology 2001 55 209-216.
26. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson B-Å, Góth MI, Wilton P & Koltowska-Häggström M. Determinants of cardiovascular risk in 2589 hypopituitary growth hormone-deficient adults. European Journal of Endocrinology 2006 155 79-90.
27. Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E & Karlsson FA. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-months trial. Journal of Clinical Endocrinology and Metabolism 1995 80 3585-3590.
28. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, Casanueva FF, Busschbach J, Koppescahaar HPF & Johansson G. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life. European Journal of Endocrinology 2006 155 109-119.
29. Colao AM, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M & Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999 84 2664-2672.